11:32 PM EST, 11/10/2026 (MT Newswires) -- Swiss drugmaker Novartis' (NOVN.SW) fully human monoclonal antibody ianalumab continued to improve systemic disease activity in patients with Sjögren's disease during the ongoing Neptunus extension study. Long-term trial data showed further reductions in systemic disease activity between week 48 and week 108 among patients receiving monthly 300-milligram doses of ianalumab. Improvements in physician- and patient-reported outcomes and salivary flow were also maintained, according to a Tuesday release. Ianalumab is under regulatory review in several countries, with a decision from the US Food and Drug Administration expected in 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.